Cavitation Technologies Faces Revenue Drop and Increased Losses Amid Challenging Operations

Cavitation Technologies, Inc. (OTCBB: CVAT) has been facing significant challenges in its operations, along with some noteworthy developments.

Key Points from the Recent Income Statement:

• Revenue: $122,000 for Q1 2025, down 76.5% from $519,000 in Q1 2024.
• Gross Profit: Reduced to $97,000 from $512,000, an 81.1% decrease.
• Net Loss: Increased to $230,000 in Q1 2025, compared to a net profit of $331,000 in Q1 2024.
• Operating Expenses: Totaled $325,000 in Q1 2025, up 81.6% year-over-year.
• General and Administrative Expenses: Rose to $283,000, an increase of 66.5% year-on-year.
• Research and Development Expenses: Surged to $42,000 from $9,000 in Q1 2024, indicating a significant investment in new technologies.
• Gain on Patent Assignment: The company recorded a gain of $880,000 due to a patent assignment agreement with Desmet in October 2024, which positively impacted net income for the nine-month period.
• Accumulated Deficit: As of March 31, 2025, the accumulated deficit stands at $26.725 million.

Positive Aspects:

• The patent assignment agreement with Desmet has provided immediate financial relief of $880,000.
• The company retains significant rights to utilize its patented technologies in relevant fields, which could open up new revenue avenues.
• Cavitation Technologies is engaging in R&D to explore further applications of its technologies, such as water and wastewater processing and agricultural applications.

Negative Aspects:

• Substantial decline in revenue from prior periods raises concerns about ongoing operations and dependency on a single major customer, Desmet.
• Operational losses have intensified, with a report of $753,000 loss from operations for the nine-month period ending March 31, 2025.
• The company is under financial strain with doubts about its ability to continue as a going concern, highlighted by its auditor's comments.

Liquidity Position:

• As of March 31, 2025, the company holds $432,000 in cash, which may not be sufficient for sustaining operations long-term.
• Management has indicated plans to seek additional financing, though there is uncertainty regarding its availability.

Cavitation Technologies remains in a precarious position with underlying operational challenges and a loss of revenue; however, strategic moves regarding its patents and a focus on R&D may provide potential pathways for recovery and future profitability.